Ekouevi Didier Koumavi, Touré Ramata, Becquet Renaud, Viho Ida, Sakarovitch Charlotte, Rouet François, Towne-Gold Besigin, Fassinou Patricia, Leroy Valériane, Blanche Stéphane, Dabis François
Unité Institut National de la Santé et de la Recherche Médicale 593, Institut de Santé Publique, Epidémiologie et Développement, Université Victor Segalen, Bordeaux, France.
Pediatrics. 2006 Oct;118(4):e1071-7. doi: 10.1542/peds.2006-0371. Epub 2006 Sep 1.
Mitochondrial toxicity was described in infants exposed to long-term antiretroviral regimens containing nucleoside analogues for the prevention of mother-to-child transmission of HIV. We measured the serum lactate levels in children born to HIV-1 infected African women receiving short-term antiretroviral prevention of mother-to-child transmission of HIV regimens.
A prospective study was conducted in women-child pairs from the third trimester of pregnancy to 3 months of life. The exposed group was formed by children exposed in utero to nucleoside analog antiretroviral regimens, zidovudine or zidovudine + lamivudine from 32 to 36 weeks of amenorrhea until delivery. All of these women received nevirapine single dose at the beginning of labor. The children received zidovudine during the first 7 days of life and a nevirapine single dose at day 3. The control group was formed by infants born to HIV-1-infected women who had received nevirapine single dose only and who were not exposed to nucleoside analog antiretroviral regimens. Serum lactate levels were measured at 4, 6, and 12 weeks of life by Cobas Integra 400.
A total of 836 blood samples from 338 infants was collected (262 exposed and 76 controls). Median lactacidemia was 1.8 mmol/L (interquartile range: 1.2-2.7 mmol/L). Overall serum lactate levels > or = 2.5 mmol/L, defining hyperlactatemia, were observed in 39 of the 292 infants who had > or = 2 serum lactate measurements. The 3-month period prevalence of hyperlactatemia did not differ between the exposed group and the control group. All of the serum lactate levels returned to normal values in all of the subsequent samples. No case of symptomatic hyperlactatemia was detected during the study period.
Increased lactate levels were identified equally in infants whose mother received short-term nucleoside analogs or nevirapine single dose for prevention of mother-to-child transmission of HIV. Although not rare, hyperlactatemia was not related to short-term exposure to nucleoside analog antiretroviral regimens.
有描述称,暴露于含核苷类似物的长期抗逆转录病毒方案以预防母婴传播HIV的婴儿中存在线粒体毒性。我们测定了感染HIV-1的非洲女性所生儿童的血清乳酸水平,这些母亲接受了短期抗逆转录病毒预防母婴传播HIV方案。
对从妊娠晚期至出生后3个月的母婴对进行了一项前瞻性研究。暴露组由在子宫内从停经32至36周直至分娩期间暴露于核苷类似物抗逆转录病毒方案、齐多夫定或齐多夫定+拉米夫定的儿童组成。所有这些女性在分娩开始时接受了奈韦拉平单剂量治疗。这些儿童在出生后的前7天接受齐多夫定治疗,并在第3天接受奈韦拉平单剂量治疗。对照组由感染HIV-1的女性所生的婴儿组成,这些女性仅接受了奈韦拉平单剂量治疗,且未暴露于核苷类似物抗逆转录病毒方案。在出生后4周、6周和12周时,使用Cobas Integra 400测定血清乳酸水平。
共收集了338名婴儿的836份血样(262名暴露组和76名对照组)。乳酸血症中位数为1.8 mmol/L(四分位间距:1.2 - 2.7 mmol/L)。在292名进行了≥2次血清乳酸测量的婴儿中,有39名观察到总体血清乳酸水平≥2.5 mmol/L,即定义为高乳酸血症。暴露组和对照组之间高乳酸血症的3个月患病率没有差异。所有后续样本中的所有血清乳酸水平均恢复到正常范围。在研究期间未检测到有症状的高乳酸血症病例。
母亲接受短期核苷类似物或奈韦拉平单剂量治疗以预防母婴传播HIV的婴儿中,乳酸水平升高的情况相当。虽然高乳酸血症并不罕见,但与短期暴露于核苷类似物抗逆转录病毒方案无关。